Accessibility StatementSkip Navigation Endometrial Cancer – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was$32.0 Million, an increase of 8.5% compared to Third Quarter of 2024 – –Â Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to$155 Million and U.S. XPOVIO Net Product Revenue Guidance of $110 Million to$120 Million – – Â Conference Call Scheduled for Today at 8:00 ...